50 patient phase II clinical trial for melanoma

Our lead product for the treatment of cancer is OncoVex GMCSF. OncoVexGMCSF is completing a 50-patient Phase II clinical trial for the treatment of unresectable metastatic melanoma, as a monotherapy, in the second line/salvage therapy setting. Data so far indicates that OncoVex can destroy both injected and un-injected melanoma deposits. The trial is still in progress.

• organism type
• Homo sapiens

• stimulus type
• OncoVexGMCSF

• experimental design type
• in vivo design experiment

created over 17 years ago (2 March 2009)    last modified over 7 years ago (21 February 2019)   [ RDF ]   [ RelFinder ]